TUKYSA is a prescription medicine used with the medicines trastuzumab and capecitabine to treat adults with human epidermal growth factor receptor-2 (HER2) positive breast cancer that has spread to other parts of the body. IPN, New Delhi can facilitate patient to import of "TUKYSA (tucatinib) tablets" for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.
Therapeutic indications and Usage
TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Active ingredient: tucatinib Inactive ingredients: Tablet core: copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose. Tablet coating: yellow film coat: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, talc, and yellow iron oxide non-irradiated.
DISEASE INDICATIONS: Breast Cancer
MANUFACTURER : Seattle Genetics
DOSAGE FORM & STRENGTHS: Tablets: 50 mg and 150 mg
MEDICINE APPROVED BY: European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Swissmedic (CH)
Source Details: Patient Information
Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "TUKYSA (tucatinib) tablets" in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Healthcare Professional In India
If you have any question, please email IPN Support Team or Call Indian Pharma Network for TUKYSA (tucatinib) tablets price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.
TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Source content : www.accessdata.fda.gov
IPN, New Delhi can facilitate patient to import of "TUKYSA (tucatinib) tablets" in small quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of TUKYSA (tucatinib) injection in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the TUKYSA (tucatinib) injection medicine cost price in India.
The order for TUKYSA (tucatinib) injection will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs
Controller General (India).
3. Availability of TUKYSA (tucatinib) from authorised distributor.
Tucatinib, sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer. It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics).
Tucatinib is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
In the European Union, it is indicated in combination with trastuzumab and capecitabine for the treatment of adults with HER2‑positive locally advanced or metastatic breast cancer who have received at least two prior anti‑HER2 treatment regimens.
TUKYSA TM (tucatinib) tablets, for oral use
Initial U.S. Approval: 2020.
Tablets: 50 mg and 150 mg
For TUKYSA (tucatinib)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Sequencing in HER2+ MBC For More Details
Tucatinib for HER2-Positive Metastatic Breast Cancer For More Details
Tucatinib, Trastuzumab, and Capecitabine May Be Efficacious in HER2+ BC With Leptomeningeal Metastasis For More Details
Step 1. Send a request for your medicine online:-
Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).Step 2. Verification of documents:-
We verify your a prescription and necessary documents to import drugs in small quantities for personal use.Step 3. Permission to Import:-
After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.Step 4. We source your medicine:-
Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.Step 5. Delivery of medicine:-
After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine. Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.
Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.
Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.
Send your query to find out -
TUKYSA (tucatinib) price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
TUKYSA (tucatinib) price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
TUKYSA (tucatinib) price in North America – Mexico.
TUKYSA (tucatinib) price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
TUKYSA (tucatinib) price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
TUKYSA (tucatinib) price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
TUKYSA (tucatinib) price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
TUKYSA (tucatinib) price in Australia and New Zealand.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.